Beone Medicines Ltd Revenue Growth Rates (ONC), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Beone Medicines Ltd   (NASDAQ: ONC)
 

ONC's Revenue Growth by Quarter and Year

Beone Medicines Ltd 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ONC Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 1,705.07
1st Quarter March 1,513.22
FY 3,218.29

ONCs Annual Revenue
Beone Medicines Ltd 's Revenue in the fiscal year 2025 $ 5,342.49 millions
Beone Medicines Ltd 's Revenue in the fiscal year 2024 $ 3,810.15 millions
Beone Medicines Ltd 's Revenue in the fiscal year 2023 $ 2,457.86 millions
Beone Medicines Ltd 's Revenue in the fiscal year 2022 $ 1,415.92 millions
Beone Medicines Ltd 's Revenue in the fiscal year 2021 $ 1,176.28 millions




ONC Revenue second quarter 2026 Y/Y Growth Comment
Beone Medicines Ltd reported Revenue improvement of 29.69% year on year in the second quarter 2026, to $ 1,705.07 millions, this is lower than Beone Medicines Ltd 's recent average Revenue rise of 74.27%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 87 other companies have achieved higher Revenue growth. While Beone Medicines Ltd ' s Revenue rise of 29.69% ranks overall at the positon no. 1575 in the second quarter 2026.


ONC Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 32.84 % 77.77 % 66.91 %
3rd Quarter September - 41.02 % 28.14 % 101.56 %
2nd Quarter June 29.69 % 41.51 % 56.07 % 74.27 %
1st Quarter March 35.44 % 48.83 % 67.65 % 46.04 %
FY   - 40.26 % 54.9 % -

Financial Statements
Beone Medicines Ltd 's second quarter 2026 Revenue $ 1,705.07 millions ONC's Income Statement
Beone Medicines Ltd 's second quarter 2025 Revenue $ 1,314.69 millions Quarterly ONC's Income Statement


ONC Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 6.12 % 12.65 % -18.8 %
3rd Quarter September - 7.38 % 7.76 % 31.26 %
2nd Quarter June 12.68 % 17.67 % 23.75 % 32.93 %
1st Quarter March 1 % -0.93 % 18.33 % 17.81 %
FY (Year on Year)   - 40.26 % 54.9 % -


Back to ONC Growth rate Comparisons >> Back to ONC Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #88
Healthcare Sector #258
Overall #1575

Revenue Y/Y Growth Statistics
High Average Low
321.42 % 74.27 % -48.23 %
(Jun 30 2021)   (Jun 30 2020)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #88
Healthcare Sector #258
Overall #1575
Revenue Y/Y Growth Statistics
High Average Low
321.42 % 74.27 % -48.23 %
(Jun 30 2021)   (Jun 30 2020)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Beone Medicines Ltd 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
57950.22 % 1439.44 % -100 %
(Jun 30 2016)  


ONC's II. Quarter Q/Q Revenue Comment
Beone Medicines Ltd achieved in the II. Quarter 2026 below company average Revenue rise of 12.68% quarter on quarter, to $ 1,705.07 millions.

Within Major Pharmaceutical Preparations industry 52 other companies have achieved higher Revenue quarter on quarter growth. While Beone Medicines Ltd 's Revenue growth quarter on quarter, overall rank is 717.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #53
Healthcare Sector #119
Overall #717
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #53
Healthcare Sector #119
Overall #717
Revenue Q/Q Growth Statistics
High Average Low
57950.22 % 1439.44 % -100 %
(Jun 30 2016)  


ONC's II. Quarter Q/Q Revenue Comment
Beone Medicines Ltd achieved in the II. Quarter 2026 below company average Revenue rise of 12.68% quarter on quarter, to $ 1,705.07 millions.

Within Major Pharmaceutical Preparations industry 52 other companies have achieved higher Revenue quarter on quarter growth. While Beone Medicines Ltd 's Revenue growth quarter on quarter, overall rank is 717.


Beone Medicines Ltd 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 6,128.24 $ 5,737.86 $ 5,341.92 $ 4,971.57 $ 4,560.93
Y / Y Revenue Growth (TTM) 34.36 % 37.42 % 40.26 % 49.96 % 47.34 %
Year on Year Revenue Growth Overall Ranking # 368 # 286 # 0 # 225 # 0
Seqeuential Revenue Change (TTM) 6.8 % 7.41 % 7.45 % 9 % 9.24 %
Seq. Revenue Growth (TTM) Overall Ranking # 1601 # 1437 # 0 # 1356 # 0


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Beone Medicines Ltd 's cumulative twelve months Revenue were $ 6,128 millions, company would post below average annual Revenue growth of 9.24% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Beone Medicines Ltd 's Revenue growth from the 1513.22% growth in Mar 31 2026.

In the Healthcare sector 94 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 286 to 368.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 88
Healthcare Sector # 95
Overall # 368

Revenue TTM Y/Y Growth Statistics
High Average Low
321.42 %
 74.27 %
-48.23 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 88
Sector # 259
S&P 500 # 1601
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Beone Medicines Ltd 's cumulative twelve months Revenue were $ 6,128 millions, company would post below average annual Revenue growth of -48.23% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Beone Medicines Ltd 's Revenue growth from the 1513.22% growth in Mar 31 2026.

In the Healthcare sector 94 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 286 to 368.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 88
Healthcare Sector # 95
Overall # 368

Revenue TTM Y/Y Growth Statistics
High Average Low
321.42 %
74.27 %
-48.23 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 88
Sector # 259
S&P 500 # 1601




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ONC's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Bioxcel Therapeutics Inc 51.67%$ 51.667 millions
Glaukos Corp50.63%$ 50.628 millions
Heartflow Inc 49.80%$ 49.801 millions
Coya Therapeutics Inc 48.97%$ 48.974 millions
Travere Therapeutics Inc 48.17%$ 48.174 millions
Halozyme Therapeutics Inc 47.67%$ 47.673 millions
Eli Lilly And Company47.67%$ 47.670 millions
Rhythm Pharmaceuticals Inc 46.91%$ 46.911 millions
Axsome Therapeutics Inc 45.54%$ 45.543 millions
Guardant Health Inc 44.33%$ 44.332 millions
Omada Health Inc 43.27%$ 43.273 millions
Mannkind Corporation42.92%$ 42.922 millions
Butterfly Network Inc 42.47%$ 42.466 millions
Beta Bionics Inc 42.26%$ 42.261 millions
Vyne Therapeutics Inc 40.58%$ 40.580 millions
Qhslab Inc 39.98%$ 39.978 millions
Coherus Oncology inc 39.53%$ 39.526 millions
Neurocrine Biosciences Inc 39.49%$ 39.491 millions
Ss Innovations International Inc39.39%$ 39.393 millions
Assembly Biosciences Inc 38.94%$ 38.936 millions
Edap Tms Sa38.85%$ 38.847 millions
Picard Medical Inc 38.62%$ 38.620 millions
Hims and Hers Health Inc 38.41%$ 38.409 millions
Aquestive Therapeutics Inc 38.15%$ 38.149 millions
Mirum Pharmaceuticals Inc 37.92%$ 37.922 millions
Natera Inc 37.71%$ 37.715 millions
Zomedica Corp 36.59%$ 36.588 millions
Kura Oncology Inc 36.54%$ 36.538 millions
Scientific Industries Inc 36.02%$ 36.022 millions
Ceribell Inc 35.85%$ 35.852 millions


About Beone Medicines Ltd Revenue Growth Rates (ONC), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Beone Medicines Ltd (CIK 1651308).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-052878
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Beone Medicines Ltd’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.